Inotiv, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2022
May 12, 2022 at 04:56 pm EDT
Share
Inotiv, Inc. reported earnings results for the second quarter and six months ended March 31, 2022. For the second quarter, the company reported revenue was USD 140.31 million compared to USD 18.75 million a year ago. Net loss was USD 6.09 million compared to USD 0.723 million a year ago. Basic loss per share from continuing operations was USD 0.24 compared to USD 0.06 a year ago.
For the six months, revenue was USD 224.52 million compared to USD 36.64 million a year ago. Net loss was USD 89.13 million compared to USD 1.09 million a year ago. Basic loss per share from continuing operations was USD 3.84 compared to USD 0.1 a year ago.
Inotiv, Inc. is a contract research company, which is engaged in providing nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries and selling a range of research-quality animals and diets to the same industries, as well as academia and government clients. Its products and services focus on bringing new drugs and medical devices through the discovery and preclinical phases of development. It operates through two segments: Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). The DSA segment supports the discovery, nonclinical development and clinical development needs of researchers and clinicians for primarily small molecule drug candidates, as well as biotherapeutics and biomedical devices. The RMS segment offer access to a range of small and large research models for basic research and drug discovery and development, as well as specialized models for specific diseases and therapeutic areas.
INOTIV, INC. 
